• contact

• |

• site map

• |

• careers

• Home
• About Us
  • Overview
  • Executive Team
  • Collaborations
  • Advisors
• Pipeline
  • Overview
  • Compounds
  • Additional Programs
  • Clinical Trials
• Families
  • Overview
  • Autism
  • Fragile X Syndrome
  • Resources
  • Join Mailing List
• Our Science
  • Overview
  • mGluR5 pathway
  • GABA-B pathway
  • Publications
• News & Events
  • News
  • Events
  • Video
  • Join Mailing List

Home › Pipeline

• Overview
• Compounds
• Additional Programs
• Clinical Trials

Related Links

• Publications

Pipeline Overview

Developing Drugs for Autism and Fragile X Syndrome

Seaside Therapeutics’ lead drug development programs are focused on creating treatments to correct or improve the course of autism and fragile X syndrome. We are also exploring opportunities to develop novel therapeutics for patients with other neurodevelopmental disorders.

© 2011 Seaside Therapeutics | Privacy Policy | Terms of Use | Join Mailing List | Log in

OK

The server encountered an internal error or misconfiguration and was unable to complete your request.

Please contact the server administrator, [no address given] and inform them of the time the error occurred, and anything you might have done that may have caused the error.

More information about this error may be available in the server error log.